ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.
- Exposure to radiation therapy is associated with female reproductive health among childhood cancer survivors: a meta-analysis study.Journal of assisted reproduction and genetics · 2015Pooled it
- Response to: Letter to the editor-Fertility after cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Letter in response to article "Fertility after cancer" by J Malhotra et al Int J Obstet Gynecol 2025;169:883-890)".International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Fertility preservation in 2026: current landscape in Europe and the United States for children and adolescents undergoing hematopoietic stem cell transplantation-recommendations on behalf of the Westhafen Intercontinental Group.Bone marrow transplantation · 2026Review
- From Maternal Exposure to F1 Development: Unveiling Cyclophosphamide-Induced Reproductive Toxicity.Biomedicines · 2026Article
- Fertility Preservation in 2026: Current Landscape in Europe and the United States for Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation - Recommendations on Behalf of the Westhafen Intercontinental Group.Transplantation and cellular therapy · 2026Review
- Leukemia during pregnancy and survivorship: gestational age-stratified multidisciplinary management framework.Clinical and experimental medicine · 2026Review
- Infertility, the outcomes of assisted reproductive technologies use in childhood cancer survivors: a scoping review.Journal of cancer survivorship : research and practice · 2026Review
- Effects of Cytotoxic Therapies on the Sperm Genome and Epigenome.Advances in experimental medicine and biology · 2026Review
- Article
- Childbirth after cancer among 42 896 male adolescents and young adults: a population-based study.Journal of the National Cancer Institute · 2025Article
- A Historical Survey of Key Epidemiological Studies of Ionizing Radiation Exposure.Radiation research · 2024Review
- Birth Defects in Offspring of Adolescent and Young Adults with a History of Cancer: A Population-Based Study of 27,000 Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Long-Term Fertility Function Sequelae in Young Male Cancer Survivors.The world journal of men's health · 2023Review
- High Resolution and Automatable Cytogenetic Biodosimetry Using In Situ Telomere and Centromere Hybridization for the Accurate Detection of DNA Damage: An Overview.International journal of molecular sciences · 2023Review
- Parenthood for childhood cancer survivors: unfounded fear of cancer development in offspring and related health behaviors.Frontiers in psychology · 2023Article
- The importance of the urologist in male oncology fertility preservation.BJU international · 2022Article
- The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment.Cancers · 2022Review
- Practices, Attitudes, and Knowledge Among Healthcare Providers and Oncologists in China Regarding Male Fertility Preservation.Frontiers in reproductive health · 2022Article
- Congenital Malformations and Perinatal Deaths Among the Children of Atomic Bomb Survivors: A Reappraisal.American journal of epidemiology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeChildren with cancer receive mutagenic treatments, which raises concern about the potential transmissibility of germline damage to their offspring. This question has been inadequately studied to date because of a lack of detailed individual treatment exposure assessment such as gonadal radiation doses.
methodsWithin the Childhood Cancer Survivor Study, we performed a retrospective cohort analysis of validated cases of congenital anomalies among 4,699 children of 1,128 male and 1,627 female childhood cancer survivors. We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes and ovaries and related these exposures to risk of congenital anomalies using logistic regression.
resultsOne hundred twenty-nine children had at least one anomaly (prevalence = 2.7%). For children whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anomalies was 3.0% versus 3.5% (P = .51); corresponding figures were 1.9% versus 1.7% (P = .79) for the children of male survivors. Neither ovarian radiation dose (mean, 1.19 Gy; odds ratio [OR] = 0.59; 95% CI, 0.20 to 1.75 for 2.50+ Gy) nor testicular radiation dose (mean, 0.48 Gy; OR = 1.01; 95% CI, 0.36 to 2.83 for 0.50+ Gy) was related to risk of congenital anomalies. Treatment with alkylating agents also was not significantly associated with anomalies in the children of male or female survivors.
conclusionOur findings offer strong evidence that the children of cancer survivors are not at significantly increased risk for congenital anomalies stemming from their parent's exposure to mutagenic cancer treatments. This information is important for counseling cancer survivors planning to have children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.